BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

10 articles for R Lou

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
22
Syntheses of novel high affinity ligands for opioid receptors.EBI
Rensselaer Polytechnic Institute
41
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.EBI
Rensselaer Polytechnic Institute
17
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.EBI
Rensselaer Polytechnic Institute
6
Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.EBI
Rensselaer Polytechnic Institute
8
3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties.EBI
Pharmacia
16
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues.EBI
Rensselaer Polytechnic Institute
43
Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines.EBI
Rensselaer Polytechnic Institute
14
8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.EBI
Rensselaer Polytechnic Institute
10
Novel small molecule guanidine Sigma1 inhibitors for advanced prostate cancer.EBI
Drexel University College of Medicine
15
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.BDB
Daiichi Sankyo